Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

NCT01041235 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Breast Cancer
Ovarian Cancer
Pancreatic Cancer
Non-Small Cell Lung

Interventions

DRUG: ATI-1123 (active drug = docetaxel)

Sponsor

Azaya Therapeutics, Inc.